| Code | CSB-RA025141MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to HBM-9378, targeting thymic stromal lymphopoietin (TSLP), a key epithelial-derived cytokine that plays a central role in allergic and inflammatory responses. TSLP is primarily produced by epithelial cells at barrier surfaces and acts as a master regulator of type 2 immune responses by activating dendritic cells, mast cells, and innate lymphoid cells. Elevated TSLP expression has been implicated in the pathogenesis of asthma, atopic dermatitis, allergic rhinitis, chronic obstructive pulmonary disease, and eosinophilic esophagitis, making it an important therapeutic target for allergic and inflammatory diseases.
HBM-9378 is a humanized monoclonal antibody developed to neutralize TSLP activity by blocking its interaction with the TSLP receptor complex. This biosimilar antibody serves as a valuable research tool for investigating TSLP-mediated signaling pathways, studying the role of epithelial-immune crosstalk in allergic inflammation, and evaluating potential therapeutic interventions targeting type 2 immunity. It enables researchers to explore disease mechanisms and validate TSLP as a target in various preclinical models.
There are currently no reviews for this product.